Abstract
Gliomas are common tumors that occur in the brain, accounting for 80% of all malignant brain tumors. Oligodendrocyte transcription factor 2 (OLIG2) is a key transcription factor and strongly expressed in gliomas, which drives proliferation and invasion of glioma cells. Our previous studies have shown that histone lysine (K) demethylase 6B (KDM6B) promotes glioma development. The data also showed that OLIG2 content was positively correlated with KDM6B. Based on this, we proposed that KDM6B may play biological roles by regulating OLIG2 expression. Subsequently, many experiments were performed including specific inhibitor treatment, gene knockdown, and chromatin immunoprecipitation (ChIP) array. These results indicated that inhibition of KDM6B enzymatic activity with GSK-J4 reduces OLIG2 gene expression and protein content. The KDM6B knockdown experiment yielded similar results, that is, it reduces the mRNA and protein level of OLIG2 in glioma cells. ChIP assay showed that the promoter of OLIG2 can be bound by KDM6B, which catalyzes the demethylation of H3K27me3 and increases the expression of OLIG2. This study reveals a new regulatory mechanism of OLIG2 by KDM6B, which has important implications for the future development of drugs for gliomas and other neurological diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. The data and materials underlying this article are available in the article.
References
Anderson JL, Muraleedharan R, Oatman N, Klotter A, Sengupta S, Waclaw RR, Wu J, Drissi R, Miles L, Raabe EH, Weirauch ML, Fouladi M, Chow LM, Hoffman L, DeWire M, Dasgupta B (2017) The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Neuro Oncol 19(8):1068–1078. https://doi.org/10.1093/neuonc/now299
Arcipowski KM, Martinez CA, Ntziachristos P (2016) Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. Curr Opin Genet Dev 36:59–67. https://doi.org/10.1016/j.gde.2016.03.010
Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27(9):985–990. https://doi.org/10.1101/gad.217778.113
Ferreira WA, Pinheiro Ddo R, Costa Junior CA, Rodrigues-Antunes S, Araújo MD, Leão Barros MB, Teixeira AC, Faro TA, Burbano RR, Oliveira EH, Harada ML, Borges Bdo N (2016) An update on the epigenetics of glioblastomas. Epigenomics 8(9):1289–1305. https://doi.org/10.2217/epi-2016-0040
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21(6):555–559. https://doi.org/10.1038/nm.3855
Greer EL, Shi Y (2012) Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 13(5):343–357. https://doi.org/10.1038/nrg3173
Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, Gupta N, Waldman TA, James CD (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20(12):1394–1396. https://doi.org/10.1038/nm.3716
Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10(5):319–331. https://doi.org/10.1038/nrc2818
Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer 14(10):651–661. https://doi.org/10.1038/nrc3811
Kasper LH, Baker SJ (2020) Invited review: emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas. Neuropathol Appl Neurobiol 46(1):73–85. https://doi.org/10.1111/nan.12591
Koehler AN (2010) A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol 14(3):331–340. https://doi.org/10.1016/j.cbpa.2010.03.022
Kooistra SM, Helin K (2012) Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13(5):297–311. https://doi.org/10.1038/nrm3327
Kosty J, Lu F, Kupp R, Mehta S, Lu QR (2017) Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas. Cell Cycle 16(18):1654–1660. https://doi.org/10.1080/15384101.2017.1361062
Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D, Hutchinson S, Jones E, Katso R, Leveridge M, Mander PK, Mosley J, Ramirez-Molina C, Rowland P, Schofield CJ, Sheppard RJ, Smith JE, Swales C, Tanner R, Thomas P, Tumber A, Drewes G, Oppermann U, Patel DJ, Lee K, Wilson DM (2012) A selective Jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488(7411):404–408. https://doi.org/10.1038/nature11262
Katagi H, Louis N, Unruh D, Sasaki T, He X, Zhang A, Ma Q, Piunti A, Shimazu Y, Lamano JB, Carcaboso AM, Tian X, Seluanov A, Gorbunova V, Laurie KL, Kondo A, Wadhwani NR, Lulla R, Goldman S, Venneti S, Becher OJ, Zou L, Shilatifard A, Hashizume R (2019) Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma. Clin Cancer Res 25(18):5572–5583. https://doi.org/10.1158/1078-0432.CCR-18-3890
Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392(10145):432–446. https://doi.org/10.1016/S0140-6736(18)30990-5
Lu F, Chen Y, Zhao C, Wang H, He D, Xu L, Wang J, He X, Deng Y, Lu EE, Liu X, Verma R, Bu H, Drissi R, Fouladi M, Stemmer-Rachamimov AO, Burns D, Xin M, Rubin JB, Bahassi EM, Canoll P, Holland EC, Lu QR (2016) Olig2-dependent reciprocal shift in PDGF and EGF receptor signaling regulates tumor phenotype and mitotic growth in malignant glioma. Cancer Cell 29(5):669–683. https://doi.org/10.1016/j.ccell.2016.03.027
Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH, Black PM (2001) Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 98(19):10851–10856. https://doi.org/10.1073/pnas.181340798
Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, Hoang-Xuan K (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358(9278):298–300. https://doi.org/10.1016/S0140-6736(01)05499-X
Masahira N, Takebayashi H, Ono K, Watanabe K, Ding L, Furusho M, Ogawa Y, Nabeshima Y, Alvarez-Buylla A, Shimizu K, Ikenaka K (2006) Olig2-positive progenitors in the embryonic spinal cord give rise not only to motoneurons and oligodendrocytes, but also to a subset of astrocytes and ependymal cells. Dev Biol 293(2):358–369. https://doi.org/10.1016/j.ydbio.2006.02.029
Meijer DH, Kane MF, Mehta S, Liu H, Harrington E, Taylor CM, Stiles CD, Rowitch DH (2012) Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2. Nat Rev Neurosci 13(12):819–831. https://doi.org/10.1038/nrn3386
Mohammad F, Helin K (2017) Oncohistones: drivers of pediatric cancers. Genes Dev 31(23–24):2313–2324. https://doi.org/10.1101/gad.309013.117
Nikolaev A, Fiveash JB, Yang ES (2020) Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int J Mol Sci 21(2):490. https://doi.org/10.3390/ijms21020490
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS (2014) The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol 16(7):896–913. https://doi.org/10.1093/neuonc/nou087
Park DH, Hong SJ, Salinas RD, Liu SJ, Sun SW, Sgualdino J, Testa G, Matzuk MM, Iwamori N, Lim DA (2014) Activation of neuronal gene expression by the JMJD3 demethylase is required for postnatal and adult brain neurogenesis. Cell Rep 8:1290–1299. https://doi.org/10.1016/j.celrep.2014.07.060
Romani M, Daga A, Forlani A, Pistillo MP, Banelli B (2019) Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells. Cancers (basel) 11(6):878. https://doi.org/10.3390/cancers11060878
Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY (2015) Medical management of brain tumors and the sequelae of treatment. Neuro Oncol 17(4):488–504. https://doi.org/10.1093/neuonc/nou304
Sui A, Xu Y, Li Y, Hu Q, Wang Z, Zhang H, Yang J, Guo X, Zhao W (2017) The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells. Oncotarget 8(40):68591–68598. https://doi.org/10.18632/oncotarget.19793
Sui A, Xu Y, Yang J, Pan B, Wu J, Guo T, Shen Y, Guo X (2019) The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1. Neurochem Int 124:123–129. https://doi.org/10.1016/j.neuint.2019.01.006
Szu J, Wojcinski A, Jiang P, Kesari S (2021) Impact of the Olig family on neurodevelopmental disorders. Front Neurosci 15:659601. https://doi.org/10.3389/fnins.2021.659601
Tsigelny IF, Kouznetsova VL, Lian N, Kesari S (2016) Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget 7(33):53074–53101. https://doi.org/10.18632/oncotarget.10628
Varier RA (1815) Timmers HT (2011) Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 1:75–89. https://doi.org/10.1016/j.bbcan.2010.10.002
Weinberg DN, Allis CD, Lu C (2017) Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb Perspect Med 7(1):a026443. https://doi.org/10.1101/cshperspect.a026443
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G (2015) Glioma Nat Rev Dis Primers 1:15017. https://doi.org/10.1038/nrdp.2015.17
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507. https://doi.org/10.1056/NEJMra0708126
Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B (2017) The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Exp Hematol 55:76-85.e3. https://doi.org/10.1016/j.exphem.2017.07.009
Acknowledgements
We acknowledge and appreciate our colleagues for their valuable suggestions.
Funding
This work was supported by Beijing non-profit foundation for medicine and health (No. YWJKJJHKYJJ-F1174B).
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: AS and XG. Performed the experiments: AS, BH, WR, WH, CG, XH, SL, YZ, and XQ. Analyzed the data: XG and AS. Wrote the paper: XG and AS. Read, edited, and approved the manuscript: All the authors.
Corresponding authors
Ethics declarations
Ethical Approval
Not applicable; our study did not have any participants and relevant information. Only human cells were used in this study, and relevant information has been indicated in the manuscript according to relevant requirements.
Consent to Participate
Not applicable; our study did not have any participants and relevant information.
Consent for Publication
Not applicable; our study did not have any participants and relevant information.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sui, A., Han, B., Ren, W. et al. The Epigenetic Regulation of OLIG2 by Histone Demethylase KDM6B in Glioma Cells. J Mol Neurosci 72, 939–946 (2022). https://doi.org/10.1007/s12031-022-01976-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-022-01976-1